Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Prilosec 1 Labeling Studies Lead To Fall 2003 Launch Target

This article was originally published in The Tan Sheet

Executive Summary

Procter & Gamble plans to introduce its nonprescription version of AstraZeneca's Prilosec (omeprazole) in the fall of 2003 based on the expectation it will obtain FDA approval for the switch in the year's third quarter
Advertisement

Related Content

P&G Crest Night Effects Positioned As Superior Paint-On Whitener
P&G Crest Night Effects Positioned As Superior Paint-On Whitener
P&G Crest Night Effects Positioned As Superior Paint-On Whitener
Colgate Herbal Whitening Leads New Product Lineup For Next Year
Prilosec 1 “approvable”
Annual Use Limitations For Prilosec 1 Should Appear In Labeling – NDAC/GDAC

Topics

Advertisement
UsernamePublicRestriction

Register

PS094741

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel